webinar register page

Webinar banner
Incubator/Accelerator/Equity - Disease Management
Incubators and accelerators are pivotal in developing innovative solutions to address humanity’s most pressing health challenges. Why are academic institutions, major medical centers, and significant life science companies launching incubators and accelerators to offer guidance to biotech, digital health, health information, and medical device start-ups? Beyond financial resources, how are these groups working to advance ideas into the marketplace, and what is their impact?

Oct 25, 2022 02:00 PM in Eastern Time (US and Canada)

Webinar logo
* Required information


Mati Gill
Mati is the CEO of AION Labs, an Israel-based innovation lab using AI for drug discovery and development, a coalition between Pfizer, Amazon Web Services (AWS), AstraZeneca, Teva, Merck and the Israel Biotech Fund (IBF). Mati has held leadership roles within the biopharma industry for over a decade, formerly serving as a senior executive at Teva Pharmaceuticals, and head of computational biology at Compugen. Mati currently sits on the board of the Israel-America Chamber of Commerce, and leads the Sanhedrin Forum for young professionals after founding it in YEAR. Prior to his term in industry, Mati was Chief of Staff for Israel’s Minister of Public Security. An IDF military veteran, Mati holds an LLB from University and an MBA in Healthcare and Innovation from Reichman University. He lives in Tel Aviv with his wife and three children.
Roy Wiesner
Managing Director, aMoon Velocity @aMoon Fund
Roy is a Managing Director at aMoon Velocity, where he leads deal teams, manages sourcing, and serves on the board of several portfolio companies. Roy has over 15 years of investment experience, first as an M&A and Private Equity lawyer in New York, Hong Kong, and Tel Aviv, and later as a venture capitalist. Before joining aMoon, Roy was the CEO of Hutchison Kinrot, a leading global incubator and seed investor in water technologies & Cleantech, owned by Hong Kong conglomerate CK Hutchison. He led numerous investments in early-stage Israeli start-ups, serving on the boards of all portfolio companies and guiding them from technological concepts to early commercialization. Prior to that, Roy was a Partner at the International M&A and Capital Markets department of a leading Israeli law firm and worked at the international law firm Weil Gotshal, where his work included representing large healthcare strategics on various financing and M&A transactions.
Johannes Fruehauf, MD, PhD
Founder and President @BioLabs and LabCentral
Johannes Fruehauf has a background as a physician working in diverse health systems. In his 15+ years as a serial biotech entrepreneur, Dr. Fruehauf has dedicated much of his professional endeavors to the mission of redefining life science entrepreneurship and building start-up ecosystems. He is the Founder and President of LabCentral, the preeminent private/public partnership model for life science incubator space, and BioLabs, the largest provider of laboratory co-working space for startups nationwide. Johannes is also Founder and General Partner of Mission BioCapital (MBC), where he sources, diligences, and leads new life science investment transactions and represents the fund on the board of a number of MBC portfolio companies. He studied medicine in Germany and France, while also conducting field work in Africa. He graduated from University of Frankfurt and received his doctorate from the University of Heidelberg.
Consuli, Inc.
Mary Howard
Program Director @Design Technologies LLC
Mary Howard is a serial entrepreneur and founder of a suite of first-time founder life sciences accelerator programs including: the Accelerator for Biosciences in CT (ABCT), Entrepreneurship Lab NYC (ELabNYC), Next Milestone and the Westchester County Biosciences Accelerator (WCBA). The free, competitive-entry ABCT and WCBA programs are now recruiting for the 2023 programs. 500 alums have raised over $2.3B advancing innovations in therapeutics, bioinformatics, diagnostics, medical devices and digital health.
Daniella Kranjac
Founding Partner @Dynamk Capital LLC
Daniella Kranjac is Founding Partner at Dynamk Capital. Daniella currently serves on the boards of Envisagenics, RoosterBio, Virica Biotech and Xcell Biosciences. She previously served on the boards of FloDesign Sonics (acquired by Millipore Sigma) and Stevens Institute of Technology, where she was a Trustee. Prior to Dynamk Capital, she was CEO and Founder of Dynamk Consulting, providing strategy and business development consulting to leading life science companies and startups. She began her career as a Co-Founder of Wave Biotech where she drove the growth of a disruptive technology, building the company and leading the group to a successful exit and acquisition by GE Healthcare in 2007. At GE, Daniella held several strategic, business development, M&A and commercial leadership roles, building a several hundred-million-dollar Enterprise Solutions business.
Philippe Michel
Chief Operating Officer @Furture4Care
Philippe MICHEL is a serial entrepreneur in the fields of innovation and IT. He is a professional coach who has been helping managers in their leadership and strategic journey for 20 years, and has collaborated in the creation of Future4care, of which he is the Chief Operation Officer. He also manages Future4care's export activities, on the one hand to help Future4care startups to develop abroad but also to prospect European startups to join the Future4care ecosystem.
Melinda Richter
Global Head, Johnson & Johnson Innovation – JLABS @Johnson & Johnson Innovation, LLC
Melinda Richter is the champion for entrepreneurs and startups, who drive potential breakthrough ideas and approaches with the goal of better health for all. She founded Johnson & Johnson Innovation – JLABS, the global incubator network of Johnson & Johnson Innovation, to connect early-stage companies to critical resources, expertise and community to support their success. Of the nearly 850 JLABS portfolio companies across 13 sites, 31% are female-led and 30% in the U.S. are minority-led, well above the industry average—demonstrating how important it is that the JLABS community reflects and speaks for the patients and global communities it hopes to serve. Melinda co-leads Johnson & Johnson Innovation’s integrated approach to address Diversity, Equity and Inclusion (DEI) in the early stages of a company’s life––when they’re creating their identity, their research focus and approach, their culture and their solutions.
Tom Daniel, MD
Board of Directors, Scripps Research; Chair, LocanaBio, Inc. @Scripps Research Institute
Tom Daniel is on the Board of Directors of Scripps Research, Chairs the Scripps Board of Overseers and is currently chairman at Locanabio, Inc. He has led research and development organizations at Immunex, Amgen, and Ambrx prior to a decade at Celgene, and served as a Venture Partner at ARCH Venture Partners in the formation and funding of Vividion Therapeutics, VIR Biotechnology Inc, SANA Biotechnology Inc. and other companies. He serves or served on the boards of several companies founded by Scripps Research scientists, including Abide Therapeutics, Aspen Neuroscience and Vividion Therapeutics. He trained in Internal Medicine, nephrology, and molecular genetics, and practiced nephrology, taught and ran a research lab and center at Vanderbilt University Medical Center.
Jérôme Van Biervliet
Managing Director, VIB Innovation & Business @VIB
Dr. Van Biervliet has 20 years cross-disciplinary experience in the medical, business and biotech environments. Prior to his position as Managing Director in the general management of VIB, he trained as a veterinary internal medicine specialist, was accredited by the American College of Veterinary Internal medicine and continued with a PhD at VIB. After his clinical and research training, Dr. Van Biervliet started as a consultant at Bain & Company. Over the last 10 years, he has been in various roles in the VIB Innovation and Business office. As the Head of Business Development, Dr. Van Biervliet is responsible for the BD team driving all industry collaborations, licensing of VIB assets and strategic collaborations. He was the founder and Head of VIB Discovery Sciences, an internal drug discovery unit at VIB creating a portfolio of innovative projects. Dr. Van Biervliet is currently Managing Director for VIB and holds end-responsibility for all of the Innovation & Business activities.